MAXIPHARMA A/S Financials, key figures and credit report
Gross profit 1 791.6 kDKK FY 2025 -16.5% vs 2024
EBIT 328.8 kDKK FY 2025 -36% vs 2024
Net debt -1 202.4 kDKK FY 2025 +25.7% vs 2024
Quick ratio 3.3 FY 2025 -0.8 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 1 682.82 | 2 022.23 | 1 824.62 | 2 144.69 | 1 791.63 |
| Employee benefit expenses | - 971.39 | -1 044.58 | -1 286.55 | -1 630.88 | -1 462.85 |
| Total depreciation | -57.15 | -7.66 | |||
| EBIT | 654.27 | 969.99 | 538.08 | 513.81 | 328.78 |
| Other financial income | 630.05 | 18.66 | 475.08 | 461.39 | 796.75 |
| Other financial expenses | -17.08 | - 648.82 | - 722.73 | - 447.49 | - 566.91 |
| Pre-tax profit | 1 267.23 | 339.83 | 290.44 | 527.71 | 558.61 |
| Income taxes | - 278.89 | -74.89 | -63.95 | - 116.39 | - 123.62 |
| Net earnings | 988.34 | 264.94 | 226.48 | 411.32 | 435.00 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Machinery and equipment | 7.66 | ||||
| Tangible assets total | 7.66 | ||||
| Investments total | 174.60 | 174.60 | 174.60 | 174.60 | 174.60 |
| Long term receivables total | |||||
| Finished products/goods | 1 607.67 | 1 564.04 | 1 228.28 | 1 004.67 | 1 462.07 |
| Inventories total | 1 607.67 | 1 564.04 | 1 228.28 | 1 004.67 | 1 462.07 |
| Current trade debtors | 1 223.16 | 1 437.05 | 1 303.41 | 1 597.26 | 1 895.43 |
| Current amounts owed by group member comp. | 225.79 | 64.31 | 104.85 | 447.34 | |
| Prepayments and accrued income | 13.49 | 25.63 | 154.57 | 128.09 | 99.02 |
| Current other receivables | 217.76 | 252.65 | |||
| Current deferred tax assets | 19.02 | 16.81 | 13.63 | ||
| Short term receivables total | 1 255.68 | 1 705.28 | 1 753.67 | 2 082.86 | 2 441.78 |
| Other current investments | 1 137.64 | 1 633.30 | 2 021.76 | 1 506.63 | 1 249.56 |
| Cash and bank deposits | 885.35 | 19.52 | 27.94 | 112.63 | 24.76 |
| Cash and cash equivalents | 2 022.99 | 1 652.81 | 2 049.71 | 1 619.26 | 1 274.32 |
| Balance sheet total (assets) | 5 068.60 | 5 096.73 | 5 206.26 | 4 881.38 | 5 352.77 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 700.00 | 700.00 | 700.00 | 700.00 | 700.00 |
| Shares repurchased | 204.00 | 204.00 | 204.00 | 204.00 | 204.00 |
| Retained earnings | 1 790.61 | 2 574.95 | 2 635.89 | 2 658.38 | 2 865.70 |
| Profit of the financial year | 988.34 | 264.94 | 226.48 | 411.32 | 435.00 |
| Shareholders equity total | 3 682.95 | 3 743.89 | 3 766.38 | 3 973.70 | 4 204.70 |
| Provisions | 11.37 | 16.65 | |||
| Non-current liabilities total | |||||
| Current loans from credit institutions | 565.82 | 602.03 | 71.96 | ||
| Current trade creditors | 122.29 | 110.61 | 117.71 | 180.25 | 242.50 |
| Current owed to group member | 214.49 | ||||
| Short-term deferred tax liabilities | 284.33 | 71.72 | 58.32 | 90.20 | 116.74 |
| Other non-interest bearing current liabilities | 764.53 | 604.69 | 661.82 | 625.86 | 700.22 |
| Current liabilities total | 1 385.65 | 1 352.84 | 1 439.88 | 896.31 | 1 131.42 |
| Balance sheet total (liabilities) | 5 068.60 | 5 096.73 | 5 206.26 | 4 881.38 | 5 352.77 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated